50% off Premium Yearly
A stage three pharmaceutical company on the smaller cap side. If it hits, it could go from $5 to $40. He prefers a basket approach to diversify risk. If they continue to miss earnings, and there is uncertainty over trade wars this could worsen.
Stock price when the opinion was issued
Build your watch list
Sign in to track investmentsyou care about
CNBC
RN Croft Financial Group
5i Research
Stockchase Premium
Private Wealth Management, ScotiaMcleod
A stage three pharmaceutical company on the smaller cap side. If it hits, it could go from $5 to $40. He prefers a basket approach to diversify risk. If they continue to miss earnings, and there is uncertainty over trade wars this could worsen.